EP2307015A4 - Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci - Google Patents

Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci

Info

Publication number
EP2307015A4
EP2307015A4 EP09803174A EP09803174A EP2307015A4 EP 2307015 A4 EP2307015 A4 EP 2307015A4 EP 09803174 A EP09803174 A EP 09803174A EP 09803174 A EP09803174 A EP 09803174A EP 2307015 A4 EP2307015 A4 EP 2307015A4
Authority
EP
European Patent Office
Prior art keywords
salts
salt
preventing
pharmaceutical composition
treating osteoporosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09803174A
Other languages
German (de)
English (en)
Other versions
EP2307015A2 (fr
Inventor
Jin Soo Lee
Yun Ha Hwang
Jei Man Ryu
Jae Hoon Park
Duk Kyun Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong Wha Pharm Co Ltd
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of EP2307015A2 publication Critical patent/EP2307015A2/fr
Publication of EP2307015A4 publication Critical patent/EP2307015A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP09803174A 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci Withdrawn EP2307015A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080075792 2008-08-01
PCT/KR2009/004277 WO2010013969A2 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci

Publications (2)

Publication Number Publication Date
EP2307015A2 EP2307015A2 (fr) 2011-04-13
EP2307015A4 true EP2307015A4 (fr) 2012-05-16

Family

ID=41610865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09803174A Withdrawn EP2307015A4 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci

Country Status (6)

Country Link
EP (1) EP2307015A4 (fr)
JP (1) JP2011529875A (fr)
KR (1) KR20100014173A (fr)
CN (1) CN102149380B (fr)
CA (1) CA2732863A1 (fr)
WO (1) WO2010013969A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007947A1 (fr) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Utilisation de derives de 4-[(4-thiazolyl)phenoxy]alcoxy-benzamidine dans le traitement de l'osteoporose
WO2006004369A1 (fr) * 2004-07-05 2006-01-12 Dong Wha Pharmaceutical. Ind. Co., Ltd. Composition pharmaceutique servant a traiter des fractures osseuses
WO2010013975A2 (fr) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
CN1144806A (zh) * 1996-07-25 1997-03-12 南京药物研究所 氨基二膦酸类骨吸收抑制剂及其钠盐的制备方法
CN1244196A (zh) * 1997-02-04 2000-02-09 同和药品工业株式会社 3－氨基－1,2－苯并异噁唑衍生物,其制备方法和应用
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
JP2003292453A (ja) * 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
JPWO2005002590A1 (ja) * 2003-07-01 2006-08-10 アステラス製薬株式会社 骨量増加誘導剤
CA2528805A1 (fr) * 2003-08-13 2005-05-06 Chiron Corporation Inhibiteurs de gsk-3 et utilisations
CA2564564A1 (fr) * 2004-04-28 2005-11-10 Merck & Co., Inc. 4-azasteroides fluores utilises en tant que modulateurs du recepteur androgene
JP2009017222A (ja) * 2007-07-04 2009-01-22 Panasonic Corp 色調整装置、色調整方法および色調整装置の集積回路

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007947A1 (fr) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Utilisation de derives de 4-[(4-thiazolyl)phenoxy]alcoxy-benzamidine dans le traitement de l'osteoporose
WO2006004369A1 (fr) * 2004-07-05 2006-01-12 Dong Wha Pharmaceutical. Ind. Co., Ltd. Composition pharmaceutique servant a traiter des fractures osseuses
WO2010013975A2 (fr) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLACK D M ET AL: "THE EFFECTS OF PARATHYROID HORMONE AND ALENDRONATE ALONE OR IN COMBINATION IN POSTMENOPAUSAL OSTEOPOROSIS", NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 13, 25 September 2003 (2003-09-25), MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, pages 1207 - 1215, XP009045315, ISSN: 1533-4406, DOI: 10.1056/NEJMOA031975 *
GREENSPAN SUSAN L ET AL: "Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: A randomized controlled trial.", JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), vol. 289, no. 19, 21 May 2003 (2003-05-21), pages 2525 - 2533+CORR, XP002672632, ISSN: 0098-7484 *

Also Published As

Publication number Publication date
KR20100014173A (ko) 2010-02-10
WO2010013969A3 (fr) 2010-05-27
WO2010013969A2 (fr) 2010-02-04
EP2307015A2 (fr) 2011-04-13
CN102149380A (zh) 2011-08-10
JP2011529875A (ja) 2011-12-15
CA2732863A1 (fr) 2010-02-04
CN102149380B (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
BRPI0923217A2 (pt) processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
ZA201100243B (en) Calcium salts of phosphorous acid for increasing the effect of fungicides
HRP20160726T1 (hr) Soli piperazina i postupak za njihovu pripravu
ZA201101439B (en) An extended release pharmaceutical composition of entacapone or salts thereof
HU0700339D0 (en) New piperazine salts and process for their preparation
HK1160849A1 (zh) 哌嗪化合物及其鹽酸鹽的製備方法
IL266097A (en) Citric acid acid salt of (R)-5-((E)-2-(pyrrolidine-3-yl)vinyl)pyrimidine, a pharmaceutical preparation containing the salt, use of the salt in the production of a medicine, salt for use, and method of production
BRPI1010300A2 (pt) processos para a preparação de um composto, para perparar dronedarone, ou um sal do mesmo, e para preparar uma formulação farmacêutica.
IL220851A0 (en) Method for preparing tetrazole methanesulfonic acid salts, and compounds used in same
ZA200904543B (en) Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation
PT2193795E (pt) Composição farmacêutica aquosa contendo latanoprost
EP2212325A4 (fr) Dérivé d' ester d'acide 2-arylméthylazetidine-carbapenem-3-carboxylique ou sels de ce dérivé, processus de préparation de ce composé et composition pharmaceutique le comprenant
WO2011155728A3 (fr) Composition destinée à prévenir ou à traiter l'ostéoporose, et procédé de fabrication de celle-ci
BRPI1008356A2 (pt) "sal de adição ácido de udenafil, respectivo método de preparação e composição farmacêutica"
EP2307016A4 (fr) Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate
IL214028A (en) A cyanopyrimidine or salt compound, a pharmaceutical preparation containing it, its use and an aqueous liquid containing the said pharmaceutical composition
IL221737A (en) Its compound or salt, a pharmaceutical preparation containing it and its uses
HUP0600198A2 (en) Duloxetine salts for producing pharmaceutical compositions, their preparation, use and impurirites
EP2269996A4 (fr) Composition médicinale contenant un composé de benzo[a]phénoxanthine comme principe actif pour la prévention ou le traitement de maladie protozoaire
BRPI0908077A2 (pt) Composição farmacêutica, métodos para prevenir ou tratar doenças, e para melhorar solubilidade em água de um composto, um sal ou uma pró-droga do mesmo
BRPI0906248A2 (pt) composto, composição farmacêutica para inibir a formação de microtúbulos e método para preparar um composto
ZA201303695B (en) Pharmaceutical composition comprising citrate and bicarbonate salts,and use thereof for treating cystinuria
EP2307015A4 (fr) Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci
HK1209022A1 (en) Amino acid derivatives used as pharmaceutical substances
EP2170878A4 (fr) Nouveaux dérivés de benzamidine, procédé de préparation correspondant et composition pharmaceutique les contenant qui permet de prévenir ou de traiter l'ostéoporose

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/10 20060101ALI20120405BHEP

Ipc: A61K 31/663 20060101ALI20120405BHEP

Ipc: A61K 31/426 20060101AFI20120405BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120416

17Q First examination report despatched

Effective date: 20130123

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130403